Interview with Paul Flapper, General Manager, Shire International Licensing BV…
Shire has many offices in America, Europe, as well as in Singapore, in Japan and in Australia. The group has a vast global network and a strong presence in these…
Address: Strawinskylaan six hundred fifty-nine
1 077 XX Amsterdam
,Netherlands
Tel: +31 (0) 20 364 00 74
Web: http://www.shirenederland.nl/
Shire is a global specialty biopharmaceutical company founded in 1986. Shire aims those with life-limiting illnesses helping a better life.
Shire seeks to achieve this through multiple therapeutic areas in medicine specialist to develop, produce and sell. Shire’s activities are housed in two divisions:
‘Human Genetic Therapies’ focused on genetic diseases such as Hunter syndrome, Fabry disease and hereditary angioedema.
Specialty Products’ represents the therapeutic areas of ADHD, Nephrology, Hematology and Gastroenterology.
Shire group is structured as two autonomous businesses supported by global corporate functions; business unit structure that enables small molecule entities to thrive under Shire Specialty Pharma and protein therapeutics to emerge from Shire Human Genetic Therapies
Shire Human Genetics Therapies delivers medicine in the therapeutic area lysosomal storage diseases, namely Fabry disease and Hunter syndrome.
Shire has many offices in America, Europe, as well as in Singapore, in Japan and in Australia. The group has a vast global network and a strong presence in these…
With almost thirty years of experience in the life sciences sector, local Dutch consultancy firm Baggerman Farma Consult offers a wide portfolio of services to its clients in the pharmaceutical…
Professor Paul Smits, Dean and Vice Chairman of Radboud University Medical Center in the Netherlands, shares his insights into the strengths of the country’s research climate and the challenges posed…
John Verhoeven, Partner and co-founder of Eagle Rock Life Sciences, a Dutch independent consultancy offering a broad range of services to both Dutch and international life sciences companies, explains how…
As Director of the Netherlands’ association for innovative medicines, Gerard Schouw outlines new strategies to enhance the Dutch research climate; foster greater collaboration between all stakeholders and improve public perception…
Manfred Rüdiger (MR), Robbert Van Heekeren (RVH) and Jeroen Rovers (JR), respectively CEO, CFO and CMO of Kiadis Pharma, a Dutch biopharmaceutical company focused on cell-based immunotherapy products for the…
After a successful IPO on Nasdaq in May 2015, Galapagos is ready to continue developing its robust portfolio of clinical-stage breakthrough therapies with the potential to revolutionize existing treatment paradigms.…
The future of drug development is about interacting, sharing and collaborating. The President and CEO of Genmab, an international biotechnology company focusing on differentiated antibody therapeutics for the treatment of…
Despite its diminutive size, the Netherlands has historically carried a large weight in the world because of certain cultural endowments: small but united, entrepreneurial, innovative, and externally oriented. During the…
Coincidentally, our meeting today comes two days after World Diabetes Day. How was this day commemorated in the Netherlands and how does it attest to the acceptance and awareness of…
Within our reports we typically like to highlight the personalities of the industry and the stories behind the executives that we meet. As you are still relatively new to Ipsen,…
In order to understand the culture behind the business that this association represents, what would you say is the perception of OTC and non-prescriptive drugs in the Netherlands? OTC medicines…
How do you operate in terms of the stakeholder management, with all of your associate members? Do you tend to operate from the committee perspective, or is there an annual…
See our Cookie Privacy Policy Here
